Inquire Before Buying - Gastroesophageal Cancer Treatment Market Share, Growth and Demand By 2027

Global Gastroesophageal Cancer Treatment Market Research Report: Forecast (2022-2027)

By Indication (Squamous Cell Carcinoma, Adenocarcinoma), By Diagnosis (Endoscopy, Biopsy, Barium Swallow X-ray, CT/PET Scans, MRI), By Treatment (Esophagectomy, Endoscopic Therapy,...... Chemotherapy (Carboplatin, Paclitaxel (Taxol), Oxaliplatin, Capecitabine, Cisplatin, 5-fluorouracil (5-FU), Others), Radiation Therapy (External-Beam Radiation Therapy (EBRT), Internal Radiation Therapy (Brachytherapy)), Immunotherapy (Keytruda (Pembrolizumab), Opdivo (Nivolumab), Yervoy (Ipilimumab)), Targeted Therapy (Trastuzumab, Enhertu (Fam-trastuzumab deruxtecan), Ramucirumab, Entrectinib, Larotrectinib)), By End-User (Hospitals, Clinics, Specialty Cancer Centers), By Region (North America, South America, Europe, Middle East & Africa, Asia-Pacific) By Country (The US, Canada, Mexico, Brazil, The UK, Germany, France, Italy, Spain, South Africa, GCC, China, Japan, India, Australia, South East Asia), By Company (AstraZeneca PLC, Amgen Inc., Bayer AG, Bristol Myers Squibb, Boehringer Ingelheim, Eli Lilly and Company, F. Hoffmann-La Roche AG, Gilead Sciences, Inc., Merck & Co., Inc., Novartis International AG, Pfizer Inc., Sanofi S.A., Others) Read more

Healthcare
Jun 2022
Pages 192
Report Format: PDF, Excel, PPT

Market Definition

Gastric & esophageal cancers are collectively known as gastroesophageal (GE) cancer and are among the leading causes of cancer deaths worldwide. Patients with early-stage GE cancer may experience dyspepsia, anorexia, dysphagia, weight loss, or abdominal pain and are often prescribed a combination of surgery & chemotherapy, with or without radiation.

There are multiple strategies for delivering neoadjuvant & adjuvant chemotherapies; however no existence of any optimal strategy. Surgery remains crucial for esophageal SCC (squamous cell carcinoma), whereas, in metastatic or unresectable diseases, there's a limited impact of traditional SOC (standard-of-care) treatments on patient outcomes.

Market Insights

The Global Gastroesophageal Cancer Treatment Market is projected to grow at around 15.8% CAGR during the forecast period, i.e., 2022-27. The growth of the market is driven primarily by the growing number of tobacco & alcohol consumers, lifestyle disorders, and the increasing prevalence of gastroesophageal reflux diseases (GERDs) & obesity.

Report Coverage	Details
Study Period	Historical Data: 2017-20
	Base Year: 2021
	Forecast Period: 2022-27
CAGR	15.8%
Regions Covered	North America: The US, Canada, Mexico
	Europe: Germany, The UK, Germany, France, Italy, Spain, Rest of Europe
	Asia-Pacific: China, Japan, India, Australia, South East Asia, Rest of Asia-Pacific
	South America: Brazil, Rest of Latin America
	Middle East & Africa: South Africa, GCC, Rest of Middle East & Africa
Key Companies Profiled	AstraZeneca PLC, Amgen Inc., Bayer AG, Bristol Myers Squibb, Boehringer Ingelheim, Eli Lilly and Company, F. Hoffmann-La Roche AG, Gilead Sciences, Inc., Merck & Co., Inc., Novartis International AG, Pfizer Inc., Sanofi S.A., Others
Unit Denominations	USD Million/Billion

The epidemiology of GE cancer has significantly transformed over several years, especially across developed countries. Since there are no early symptoms, esophageal cancer is diagnosed mainly at advanced stages. It owes prominently to heavy smoking & alcohol usage and growing instances of diseases like gastroesophageal reflux, obesity, & gastric ulcer, among others, which increase the risk of developing gastric cancer.

Even with significant developments in multimodality treatments, the prognosis for GE cancer is still inadequate, with a below 20% 5-year survival rate. However, rapid approvals for the combined use of systemic therapies & new targeted agents as first-line treatments are projected to generate growth opportunities for the Global Gastroesophageal Cancer Market through 2027.

Additionally, the remarkable efficacy of immune checkpoint inhibitors, especially Opdivo & Keytruda, would further augment the market expansion in the nearer future. Various targeted therapies in late-stage development, coupled with easy insurance reimbursements, are also anticipated to boost the market in the years to come.

However, aspects like the high costs of therapies and their adverse effects like mouth sores, loss of appetite, hair loss, diarrhea, etc., which can greatly damage some vital nerves of the body, might hinder the growth of the Global Gastroesophageal Cancer Treatment Market during 2022-27.

Introduction
1. Research Process
2. Assumption
3. Market Segmentation
4. Market Definition
Executive Summary
Global Gastroesophageal Cancer Treatment Market Trends & Insights
Global Gastroesophageal Cancer Treatment Market Regulation & Policy, By Country
Global Gastroesophageal Cancer Treatment Market Dynamics
1. Growth Drivers
2. Challenges
3. Impact Analysis
Global Gastroesophageal Cancer Treatment Market Hotspot and Opportunities
Global Gastroesophageal Cancer Treatment Market Outlook, 2017- 2027
1. Market Size and Analysis
  1. By Revenues in USD Million
2. Market Share and Analysis
  1. By Indication
    1. Squamous Cell Carcinoma
    2. Adenocarcinoma
  2. By Diagnosis
    1. Endoscopy
    2. Biopsy
    3. Barium Swallow X-ray
    4. CT/PET Scans
    5. MRI
  3. By Treatment
    1. Esophagectomy
    2. Endoscopic Therapy
    3. Chemotherapy
      1. Carboplatin
      2. Paclitaxel (Taxol)
      3. Oxaliplatin
      4. Capecitabine
      5. Cisplatin
      6. 5-fluorouracil (5-FU)
      7. Others
    4. Radiation Therapy
      1. External-Beam Radiation Therapy (EBRT)
      2. Internal radiation therapy (Brachytherapy)
    5. Immunotherapy
      1. Keytruda (Pembrolizumab)
      2. Opdivo (Nivolumab)
      3. Yervoy (Ipilimumab)
    6. Targeted Therapy
      1. Trastuzumab
      2. Enhertu (Fam-trastuzumab deruxtecan)
      3. Ramucirumab
      4. Entrectinib
      5. Larotrectinib
  4. By End-User
    1. Hospitals
    2. Clinics
    3. Specialty Cancer Centers
  5. By Region
    1. North America
    2. South America
    3. Europe
    4. Middle East & Africa
    5. Asia-Pacific
  6. By Company
    1. Competition Characteristics
    2. Revenue Shares
    3. Competitor Placement in MarkNtel Advisor’s Quadrant
North America Gastroesophageal Cancer Treatment Market Outlook, 2017- 2027
1. Market Size and Analysis
  1. By Revenues in USD Million
2. Market Share and Analysis
  1. By Indication
  2. By Diagnosis
  3. By Treatment
  4. By End-User
  5. By Country
    1. The US
    2. Canada
    3. Mexico
South America Gastroesophageal Cancer Treatment Market Outlook, 2017- 2027
1. Market Size and Analysis
  1. By Revenues in USD Million
2. Market Share and Analysis
  1. By Indication
  2. By Diagnosis
  3. By Treatment
  4. By End-User
  5. By Country
    1. Brazil
    2. Rest of Latin America
Europe Gastroesophageal Cancer Treatment Market Outlook, 2017- 2027
1. Market Size and Analysis
  1. By Revenues in USD Million
2. Market Share and Analysis
  1. By Indication
  2. By Diagnosis
  3. By Treatment
  4. By End-User
  5. By Country
    1. The UK
    2. Germany
    3. France
    4. Italy
    5. Spain
    6. Rest of Europe
Middle East & Africa Gastroesophageal Cancer Treatment Market Outlook, 2017- 2027
1. Market Size and Analysis
  1. By Revenues in USD Million
2. Market Share and Analysis
  1. By Indication
  2. By Diagnosis
  3. By Treatment
  4. By End-User
  5. By Country
    1. South Africa
    2. GCC
    3. Rest of Middle East & Africa
Asia-Pacific Gastroesophageal Cancer Treatment Market Outlook, 2017- 2027
1. Market Size and Analysis
  1. By Revenues in USD Million
2. Market Share and Analysis
  1. By Indication
  2. By Diagnosis
  3. By Treatment
  4. By End-User
  5. By Country
    1. China
    2. Japan
    3. India
    4. Australia
    5. South East Asia
    6. Rest of Asia-Pacific
Global Gastroesophageal Cancer Treatment Market Key Strategic Imperatives for Success and Growth
Competitive Outlook
1. Competition Matrix
  1. By Application Portfolio
  2. Brand Specialization
  3. Target Markets
  4. Target by Applications
  5. Research & Development
  6. Strategic Alliances
  7. Strategic Initiatives
2. Company Profiles (Business Description, By Application Segments, Business Segments, Financials, Strategic Alliances/ Partnerships, Future Plans)
  1. AstraZeneca PLC
  2. Amgen Inc.
  3. Bayer AG
  4. Bristol Myers Squibb
  5. Boehringer Ingelheim
  6. Eli Lilly and Company
  7. F. Hoffmann-La Roche AG
  8. Gilead Sciences, Inc.
  9. Merck & Co., Inc.
  10. Novartis International AG
  11. Pfizer Inc.
  12. Sanofi S.A.
  13. Others
Disclaimer

MarkNtel Advisors follows a robust and iterative research methodology designed to ensure maximum accuracy and minimize deviation in market estimates and forecasts. Our approach combines both bottom-up and top-down techniques to effectively segment and quantify various aspects of the market. A consistent feature across all our research reports is data triangulation, which examines the market from three distinct perspectives to validate findings. Key components of our research process include:

1. Scope & Research Design At the outset, MarkNtel Advisors define the research objectives and formulate pertinent questions. This phase involves determining the type of research—qualitative or quantitative—and designing a methodology that outlines data collection methods, target demographics, and analytical tools. They also establish timelines and budgets to ensure the research aligns with client goals.

2. Sample Selection and Data Collection In this stage, the firm identifies the target audience and determines the appropriate sample size to ensure representativeness. They employ various sampling methods, such as random or stratified sampling, based on the research objectives. Data collection is carried out using tools like surveys, interviews, and observations, ensuring the gathered data is reliable and relevant.

3. Data Analysis and Validation Once data is collected, MarkNtel Advisors undertake a rigorous analysis process. This includes cleaning the data to remove inconsistencies, employing statistical software for quantitative analysis, and thematic analysis for qualitative data. Validation steps are taken to ensure the accuracy and reliability of the findings, minimizing biases and errors.

4. Data Forecast and FinalizationThe final phase involves forecasting future market trends based on the analyzed data. MarkNtel Advisors utilize predictive modeling and time series analysis to anticipate market behaviors. The insights are then compiled into comprehensive reports, featuring visual aids like charts and graphs, and include strategic recommendations to inform client decision-making

FILL THE FORM TO INQUIRE BEFORE BUYING THIS REPORT

Name *

Email ID *

Country *